View ValuationConsun Pharmaceutical Group 将来の成長Future 基準チェック /36Consun Pharmaceutical Group利益と収益がそれぞれ年間11.8%と11.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に24.4% 11.9%なると予測されています。主要情報11.8%収益成長率11.88%EPS成長率Pharmaceuticals 収益成長14.4%収益成長率11.8%将来の株主資本利益率24.40%アナリストカバレッジLow最終更新日30 Mar 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 26Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026.お知らせ • Mar 05Consun Pharmaceutical Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Consun Pharmaceutical Group Limited announced that they will report fiscal year 2025 results on Mar 26, 2026お知らせ • Aug 19Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2025 , Payable on September 19, 2025Consun Pharmaceutical Group Limited announced Interim Dividend of HKD 0.33 per share for the six months ended 30 June 2025. Ex-dividend date: 04 September 2025, Record date: 05 September 2025. Payment date: 19 September 2025.お知らせ • Aug 06Consun Pharmaceutical Group Limited to Report First Half, 2025 Results on Aug 19, 2025Consun Pharmaceutical Group Limited announced that they will report first half, 2025 results on Aug 19, 2025お知らせ • Jun 20Consun Pharmaceutical Group Limited Announces Nomination Committee Changes, Effective from 20 June 2025Consun Pharmaceutical Group Limited announced the following changes in the composition of the nomination committee of the Board (the "Nomination Committee") with effect from 20 June 2025. Mr. An Meng, the chairman of the Board and an executive Director, has ceased to be a member of the Nomination Committee; and Dr. Zhang Lihua, a non-executive Director, has been appointed as a member of the Nomination Committee. Following the above changes, the Nomination Committee will comprise three members, namely Professor Li Yikai (chairman), Dr. Zhang Lihua, and Mr. Duan Weiwu.お知らせ • May 22Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2024Consun Pharmaceutical Group Limited announced that at the AGM held on May 22, 2025 approved to pay to the shareholders of the Company a final dividend of HKD 0.3 per ordinary share of the Company for the year ended 31 December 2024.お知らせ • Apr 08Consun Pharmaceutical Group Limited Announces Executive and Committee ChangesConsun Pharmaceutical Group Limited announced that with effect from 8 April 2025, Mr. Young Yuk Chuen David ("Mr. Young") has been appointed as an executive Director, the overseas business director and a member of the environmental, social and governance committee (the "ESG Committee"); and Mr. Duan Weiwu (" Mr. Duan ") has been appointed as an independent non-executive Director, and a member of the audit committee (the "Audit Committee") and the nomination. Mr. Young Yuk Chuen David, aged 27, has obtained his bachelor's degree of science,in operations management and management and leadership from Boston College in May 2020 and his master's degree in management from Institut Européen d'Administration des Affaires (INSEAD) in June 2022. He also holds certificates of PMI Disciplined Agile Scrum Master, ASQ Six Sigma Yellow Belt, CAIA Fundamentals of Alternative Investments & Private Debt, Series 65. Mr. Young will be responsible for the participation in the introduction of the Group's international investment projects and development for overseas business. Mr. Young has extensive experience in researching international macro and fundamental investment strategies. He has been serving as the managing director of Champ Standard, an investment management firm, since July 2023. Mr. Young is the son of Mr. Young Wai Po, Peter, a substantial shareholder of the Company, who owns all issued shares of Guidoz Limited, which in turn owns 110,050,000 shares of the Company (representing approximately 12.94% of the total issued shares of the Company as at the date of this announcement).Mr. Duan Weiwu aged 49, is a lawyer qualified in the PRC and has over 20 years of experience in the provision of commercial legal services. He has been a partner of Dacheng Guangzhou office of Beijing Dacheng Law Offices, LLP since October 2019. From October 2006 to October 2019, Mr. Duan served as a lawyer and has been promoted to senior partner at Guangdong Jinglun Law Firm in 2016. Mr. Duan obtained his bachelor's degree in law from Zhongnan Institute of Law (now known as Zhongnan University of Economics and Law in 1999 with and his master's degree in law from Sun Yat-sen University in 2007. He is also an arbitrator of Guangzhou Arbitration Commission and Wuhan Arbitration Commission. Mr. Duan has extensive experience in the fields of pharmaceutical commerce, pharmaceutical research and development, and legal services for pharmaceutical commercial transactions. He has been selected as a "Recommended Lawyer" in the field of life sciences and healthcare legal services in the legal market in Greater China for 2025 published by The Legal 500, an international authoritative legal rating agency. The Board further announces that with effect from 8 April 2025, (i) Mr. Feng Zhongshi, an independent non-executive Director, ceased to be a member of the Audit Committee; and (ii) Mr. Li Zhuoguang, an independent non-executive Director, ceased to be a member of the Nomination Committee and the ESG Committee.お知らせ • Mar 26+ 1 more updateConsun Pharmaceutical Group Limited, Annual General Meeting, May 22, 2025Consun Pharmaceutical Group Limited, Annual General Meeting, May 22, 2025.お知らせ • Mar 13Consun Pharmaceutical Group Limited Announces First Cohort of Subjects Dosed for A Phase 1 Clinical Trial of SK-08 TabletConsun Pharmaceutical Group Limited announced that the Group is conducting a Phase 1 trial for evaluating the safety, tolerability and pharmacokinetic of SK-08 Tablet. The first cohort of subjects has been successfully dosed. Chronic kidney disease ("CKD") represents a significant global public health challenge, posing severe risks to human health. In the PRC, the number of affected individuals has exceeded 100 million, with the incidence rate showing a consistent upward trend year by year. Patients with CKD experience a progressive decline in renal function, which may ultimately progress to end-stage renal disease (ESRD), necessitating dialysis or kidney transplantation. This imposes substantial physical, emotional, and financial burdens on patients and their families. SK-08 Tablet is a Category 1 innovative drug with global intellectual property rights jointly developed by the Group and another pharmaceutical company. Its unique mechanism of action precisely targets soluble guanylate cyclase (sGC), which is independent of the presence of nitric oxide, and promotes the generation of cGMP, which in turn can help reduce proteinuria and safeguard the functions of the kidney through multiple biological effects such as vasodilation, increasing kidney blood supply, improving glomerular filtration rate, anti-inflammation and anti-fibrosis. Additionally, it regulates reabsorption in the kidney, enhances cardiac function and mitigates the risks of thrombosis. In preclinical trials, SK-08 Tablet significantly reduced proteinuria, improved kidney functions and alleviated glomerulosclerosis, and was well tolerated with good safety profile. Currently, there is no other drug adopting similar mechanism approved for the treatment of CKD across the world. SK-08 Tablet is expected to fill this gap and will provide a new treatment option for patients with CKD. The Group envisages to promote prioritization of kidney health, early screening and prevention, and actively explore innovative treatment solutions, and the successful dosing of the first cohort of subjects marks another significant milestone for the Group in the development of innovative therapeutics for kidney disease. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.お知らせ • Mar 05Consun Pharmaceutical Group Limited to Report Fiscal Year 2024 Results on Mar 26, 2025Consun Pharmaceutical Group Limited announced that they will report fiscal year 2024 results on Mar 26, 2025お知らせ • Feb 25Consun Pharmaceutical Group Limited Announces CFO ChangesThe board of directors of Consun Pharmaceutical Group Limited announced that with effect from 24 February 2025, Mr. Fang Peicheng, formerly the vice president and chief financial officer of the Group, ceased to concurrently serve as Chief Financial Officer and continued to hold the position of vice president of the Group. Ms. Chen has been appointed as the Chief Financial Officer with effect from 24 February 2025. Ms. Chen Yujun served as an independent non-executive Director and among others, acted as the chairlady of the Audit Committee with appropriate professional qualifications and accounting expertise, from 31 May 2019 to immediately prior to the Resignation.お知らせ • Feb 24Consun Pharmaceutical Group Limited Announces Board and Committee ChangesThe board of directors of Consun Pharmaceutical Group Limited announced that with effect from 24 February 2025: Ms. Chen Yujun has resigned as an independent non-executive Director, and ceased to be the chairlady of the audit committee, and a member of the nomination committee, the remuneration committee and the environmental, social and governance committee and Mr. Li Zhuoguang has been appointed as an independent non-executive Director, the chairman of the Audit Committee, and a member of the Nomination Committee, the Remuneration Committee and the ESG Committee in place of Ms. Chen. The Resignation took effect from 24 February 2025, due to the reallocation of responsibilities in the Group's management. The Appointment took effect from 24 February 2025. Mr. Li, aged 42, has around 20 years of experience in audit and accounting works in the PRC. Mr. Li has been working for GUANGZHOU HEYGEARS IMC. INCas an executive director and assistant to the chairman of the board since August 2023. From January 2013 to June 2023, Mr. Li worked for Jiumaojiu International Holdings Limited,a company whose shares are listed on the Stock Exchange (stock code: 9922), and his last position was executive director and chief financial officer of Jiumaojiu and vice president of Guangzhou Jiumaojiu Catering Chain Co. Ltd. He worked at Tianji Real Estate Development (Shenzhen) Co., Lt, a real property development company as vice financial controller from April to December 2012 and KPMG Huazhen LLP as manager dfrom June 2005 to April 2012. Mr. Li became a member of the Chinese Institute of Certified Public Accountants in August 2008. He graduated from Sun Yat-sen University in July 2005 with a bachelor's degree in English.業績と収益の成長予測OTCPK:CPHG.F - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20284,9181,5461,234N/A212/31/20274,3011,3881,046N/A312/31/20263,8831,244912N/A212/31/20253,4171,078N/AN/AN/A9/30/20253,3421,044N/AN/AN/A6/30/20253,2671,0091,1431,229N/A3/31/20253,1179601,0611,158N/A12/31/20242,9679109781,087N/A9/30/20242,8538739051,001N/A6/30/20242,739836833915N/A3/31/20242,665810800867N/A12/31/20232,590785766819N/A9/30/20232,528759797844N/A6/30/20232,466734828869N/A3/31/20232,403708862908N/A12/31/20222,340683896948N/A9/30/20222,246660836906N/A6/30/20222,152636776865N/A3/31/20222,098613701795N/A12/31/20212,045590627726N/A9/30/20211,959565655731N/A6/30/20211,874541683737N/A3/31/20211,813520748802N/A12/31/20201,753499813867N/A9/30/20201,653269639717N/A6/30/20201,55339465567N/A3/31/20201,64160334475N/A12/31/20191,72880203383N/A9/30/20191,822288N/A442N/A6/30/20191,916496N/A501N/A3/31/20191,880481N/A628N/A12/31/20181,844465N/A754N/A9/30/20181,802448N/A662N/A6/30/20181,760430N/A570N/A3/31/20181,710413N/A411N/A12/31/20171,660396N/A252N/A9/30/20171,601372N/A323N/A6/30/20171,541347N/A393N/A3/31/20171,382327N/A421N/A12/31/20161,223308N/A449N/A9/30/20161,060291N/A362N/A6/30/2016896274N/A275N/A3/31/2016863262N/A230N/A12/31/2015831250N/A184N/A9/30/2015814246N/A180N/A6/30/2015798242N/A175N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CPHG.Fの予測収益成長率 (年間11.8% ) は 貯蓄率 ( 3.4% ) を上回っています。収益対市場: CPHG.Fの収益 ( 11.8% ) US市場 ( 16.8% ) よりも低い成長が予測されています。高成長収益: CPHG.Fの収益は増加すると予測されていますが、大幅には増加しません。収益対市場: CPHG.Fの収益 ( 11.8% ) US市場 ( 11.6% ) よりも速いペースで成長すると予測されています。高い収益成長: CPHG.Fの収益 ( 11.8% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CPHG.Fの 自己資本利益率 は、3年後には高くなると予測されています ( 24.4 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/04/04 07:19終値2026/01/05 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Consun Pharmaceutical Group Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Zhuhong ChenChina Merchants Securities (HK) Co., Ltdnull nullCMB International Securities LimitedWai Ming KongDBS Bank Ltd2 その他のアナリストを表示
お知らせ • Mar 26Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026Consun Pharmaceutical Group Limited, Annual General Meeting, May 26, 2026.
お知らせ • Mar 05Consun Pharmaceutical Group Limited to Report Fiscal Year 2025 Results on Mar 26, 2026Consun Pharmaceutical Group Limited announced that they will report fiscal year 2025 results on Mar 26, 2026
お知らせ • Aug 19Consun Pharmaceutical Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2025 , Payable on September 19, 2025Consun Pharmaceutical Group Limited announced Interim Dividend of HKD 0.33 per share for the six months ended 30 June 2025. Ex-dividend date: 04 September 2025, Record date: 05 September 2025. Payment date: 19 September 2025.
お知らせ • Aug 06Consun Pharmaceutical Group Limited to Report First Half, 2025 Results on Aug 19, 2025Consun Pharmaceutical Group Limited announced that they will report first half, 2025 results on Aug 19, 2025
お知らせ • Jun 20Consun Pharmaceutical Group Limited Announces Nomination Committee Changes, Effective from 20 June 2025Consun Pharmaceutical Group Limited announced the following changes in the composition of the nomination committee of the Board (the "Nomination Committee") with effect from 20 June 2025. Mr. An Meng, the chairman of the Board and an executive Director, has ceased to be a member of the Nomination Committee; and Dr. Zhang Lihua, a non-executive Director, has been appointed as a member of the Nomination Committee. Following the above changes, the Nomination Committee will comprise three members, namely Professor Li Yikai (chairman), Dr. Zhang Lihua, and Mr. Duan Weiwu.
お知らせ • May 22Consun Pharmaceutical Group Limited Approves Final Dividend for the Year Ended 31 December 2024Consun Pharmaceutical Group Limited announced that at the AGM held on May 22, 2025 approved to pay to the shareholders of the Company a final dividend of HKD 0.3 per ordinary share of the Company for the year ended 31 December 2024.
お知らせ • Apr 08Consun Pharmaceutical Group Limited Announces Executive and Committee ChangesConsun Pharmaceutical Group Limited announced that with effect from 8 April 2025, Mr. Young Yuk Chuen David ("Mr. Young") has been appointed as an executive Director, the overseas business director and a member of the environmental, social and governance committee (the "ESG Committee"); and Mr. Duan Weiwu (" Mr. Duan ") has been appointed as an independent non-executive Director, and a member of the audit committee (the "Audit Committee") and the nomination. Mr. Young Yuk Chuen David, aged 27, has obtained his bachelor's degree of science,in operations management and management and leadership from Boston College in May 2020 and his master's degree in management from Institut Européen d'Administration des Affaires (INSEAD) in June 2022. He also holds certificates of PMI Disciplined Agile Scrum Master, ASQ Six Sigma Yellow Belt, CAIA Fundamentals of Alternative Investments & Private Debt, Series 65. Mr. Young will be responsible for the participation in the introduction of the Group's international investment projects and development for overseas business. Mr. Young has extensive experience in researching international macro and fundamental investment strategies. He has been serving as the managing director of Champ Standard, an investment management firm, since July 2023. Mr. Young is the son of Mr. Young Wai Po, Peter, a substantial shareholder of the Company, who owns all issued shares of Guidoz Limited, which in turn owns 110,050,000 shares of the Company (representing approximately 12.94% of the total issued shares of the Company as at the date of this announcement).Mr. Duan Weiwu aged 49, is a lawyer qualified in the PRC and has over 20 years of experience in the provision of commercial legal services. He has been a partner of Dacheng Guangzhou office of Beijing Dacheng Law Offices, LLP since October 2019. From October 2006 to October 2019, Mr. Duan served as a lawyer and has been promoted to senior partner at Guangdong Jinglun Law Firm in 2016. Mr. Duan obtained his bachelor's degree in law from Zhongnan Institute of Law (now known as Zhongnan University of Economics and Law in 1999 with and his master's degree in law from Sun Yat-sen University in 2007. He is also an arbitrator of Guangzhou Arbitration Commission and Wuhan Arbitration Commission. Mr. Duan has extensive experience in the fields of pharmaceutical commerce, pharmaceutical research and development, and legal services for pharmaceutical commercial transactions. He has been selected as a "Recommended Lawyer" in the field of life sciences and healthcare legal services in the legal market in Greater China for 2025 published by The Legal 500, an international authoritative legal rating agency. The Board further announces that with effect from 8 April 2025, (i) Mr. Feng Zhongshi, an independent non-executive Director, ceased to be a member of the Audit Committee; and (ii) Mr. Li Zhuoguang, an independent non-executive Director, ceased to be a member of the Nomination Committee and the ESG Committee.
お知らせ • Mar 26+ 1 more updateConsun Pharmaceutical Group Limited, Annual General Meeting, May 22, 2025Consun Pharmaceutical Group Limited, Annual General Meeting, May 22, 2025.
お知らせ • Mar 13Consun Pharmaceutical Group Limited Announces First Cohort of Subjects Dosed for A Phase 1 Clinical Trial of SK-08 TabletConsun Pharmaceutical Group Limited announced that the Group is conducting a Phase 1 trial for evaluating the safety, tolerability and pharmacokinetic of SK-08 Tablet. The first cohort of subjects has been successfully dosed. Chronic kidney disease ("CKD") represents a significant global public health challenge, posing severe risks to human health. In the PRC, the number of affected individuals has exceeded 100 million, with the incidence rate showing a consistent upward trend year by year. Patients with CKD experience a progressive decline in renal function, which may ultimately progress to end-stage renal disease (ESRD), necessitating dialysis or kidney transplantation. This imposes substantial physical, emotional, and financial burdens on patients and their families. SK-08 Tablet is a Category 1 innovative drug with global intellectual property rights jointly developed by the Group and another pharmaceutical company. Its unique mechanism of action precisely targets soluble guanylate cyclase (sGC), which is independent of the presence of nitric oxide, and promotes the generation of cGMP, which in turn can help reduce proteinuria and safeguard the functions of the kidney through multiple biological effects such as vasodilation, increasing kidney blood supply, improving glomerular filtration rate, anti-inflammation and anti-fibrosis. Additionally, it regulates reabsorption in the kidney, enhances cardiac function and mitigates the risks of thrombosis. In preclinical trials, SK-08 Tablet significantly reduced proteinuria, improved kidney functions and alleviated glomerulosclerosis, and was well tolerated with good safety profile. Currently, there is no other drug adopting similar mechanism approved for the treatment of CKD across the world. SK-08 Tablet is expected to fill this gap and will provide a new treatment option for patients with CKD. The Group envisages to promote prioritization of kidney health, early screening and prevention, and actively explore innovative treatment solutions, and the successful dosing of the first cohort of subjects marks another significant milestone for the Group in the development of innovative therapeutics for kidney disease. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.
お知らせ • Mar 05Consun Pharmaceutical Group Limited to Report Fiscal Year 2024 Results on Mar 26, 2025Consun Pharmaceutical Group Limited announced that they will report fiscal year 2024 results on Mar 26, 2025
お知らせ • Feb 25Consun Pharmaceutical Group Limited Announces CFO ChangesThe board of directors of Consun Pharmaceutical Group Limited announced that with effect from 24 February 2025, Mr. Fang Peicheng, formerly the vice president and chief financial officer of the Group, ceased to concurrently serve as Chief Financial Officer and continued to hold the position of vice president of the Group. Ms. Chen has been appointed as the Chief Financial Officer with effect from 24 February 2025. Ms. Chen Yujun served as an independent non-executive Director and among others, acted as the chairlady of the Audit Committee with appropriate professional qualifications and accounting expertise, from 31 May 2019 to immediately prior to the Resignation.
お知らせ • Feb 24Consun Pharmaceutical Group Limited Announces Board and Committee ChangesThe board of directors of Consun Pharmaceutical Group Limited announced that with effect from 24 February 2025: Ms. Chen Yujun has resigned as an independent non-executive Director, and ceased to be the chairlady of the audit committee, and a member of the nomination committee, the remuneration committee and the environmental, social and governance committee and Mr. Li Zhuoguang has been appointed as an independent non-executive Director, the chairman of the Audit Committee, and a member of the Nomination Committee, the Remuneration Committee and the ESG Committee in place of Ms. Chen. The Resignation took effect from 24 February 2025, due to the reallocation of responsibilities in the Group's management. The Appointment took effect from 24 February 2025. Mr. Li, aged 42, has around 20 years of experience in audit and accounting works in the PRC. Mr. Li has been working for GUANGZHOU HEYGEARS IMC. INCas an executive director and assistant to the chairman of the board since August 2023. From January 2013 to June 2023, Mr. Li worked for Jiumaojiu International Holdings Limited,a company whose shares are listed on the Stock Exchange (stock code: 9922), and his last position was executive director and chief financial officer of Jiumaojiu and vice president of Guangzhou Jiumaojiu Catering Chain Co. Ltd. He worked at Tianji Real Estate Development (Shenzhen) Co., Lt, a real property development company as vice financial controller from April to December 2012 and KPMG Huazhen LLP as manager dfrom June 2005 to April 2012. Mr. Li became a member of the Chinese Institute of Certified Public Accountants in August 2008. He graduated from Sun Yat-sen University in July 2005 with a bachelor's degree in English.